Format

Send to

Choose Destination
See comment in PubMed Commons below
Osteoporos Int. 2007 Mar;18(3):271-7. Epub 2006 Oct 5.

Compliance with osteoporosis drug therapy and risk of fracture.

Author information

1
Policy Analysis Inc. (PAI), Four Davis Court, Brookline, MA 02445, USA. dweycker@pai2.com

Abstract

INTRODUCTION:

Patient compliance with osteoporosis drug therapy is often poor in clinical practice and may be associated with higher risk of fracture.

METHODS:

A nested case-control study was undertaken using a US health insurance claims database. The source population included all women aged >or=45 years who began drug therapy for osteoporosis. Cases consisted of those who experienced an osteoporosis-related fracture; they were matched to controls without osteoporosis-related fracture. Compliance with osteoporosis drug treatment was assessed in terms of the number of therapy-days received and medication possession ratio (MPR). Conditional logistic regression was employed to examine the relationship between compliance and fracture risk.

RESULTS:

A total of 453 women with osteoporosis-related fracture were identified and matched to 2,160 controls. Fracture risk was significantly lower for patients with >180 days of therapy [181-360 days: odds ratio (OR) = 0.70, 95% CI = 0.49-0.99; >360 days: OR = 0.65, 95% CI = 0.43-0.99) versus those with <or=30 days. Risk was also lower for patients with MPR >or=90% (OR = 0.70, 95% CI = 0.52-0.93) versus those with MPR <30%. Fracture risk decreased as compliance increased (p(trend) < 0.05).

CONCLUSION:

Among women initiating drug therapy for osteoporosis, better compliance is associated with reduced risk of fracture.

PMID:
17021945
DOI:
10.1007/s00198-006-0230-y
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center